Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.